Atlas Trials

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Clinical trial NCT07677267 · RECRUITING

Trial details

NCT number
NCT07677267
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Study type
OBSERVATIONAL
Prostatic Neoplasms, Castration-Resistant
Start date
2026-06-30
Primary completion
2026-11-30
Enrollment
1067

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.